- Home
- SISI vs MNPR Comparison
SISI vs MNPR Comparison
Compare SISI & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SISI
- MNPR
- Stock Information
- Founded
- SISI 1997
- MNPR 2014
- Country
- SISI China
- MNPR United States
- Employees
- SISI N/A
- MNPR N/A
- Industry
- SISI Medicinal Chemicals and Botanical Products
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- SISI Health Care
- MNPR Health Care
- Exchange
- SISI Nasdaq
- MNPR Nasdaq
- Market Cap
- SISI 227.4M
- MNPR 248.8M
- IPO Year
- SISI 2016
- MNPR 2019
- Fundamental
- Price
- SISI $7.78
- MNPR $57.37
- Analyst Decision
- SISI
- MNPR Strong Buy
- Analyst Count
- SISI 0
- MNPR 11
- Target Price
- SISI N/A
- MNPR $68.60
- AVG Volume (30 Days)
- SISI 1.6M
- MNPR 39.6K
- Earning Date
- SISI 11-13-2025
- MNPR 11-07-2025
- Dividend Yield
- SISI N/A
- MNPR N/A
- EPS Growth
- SISI N/A
- MNPR N/A
- EPS
- SISI N/A
- MNPR N/A
- Revenue
- SISI $9,601,324.00
- MNPR N/A
- Revenue This Year
- SISI N/A
- MNPR N/A
- Revenue Next Year
- SISI N/A
- MNPR N/A
- P/E Ratio
- SISI N/A
- MNPR N/A
- Revenue Growth
- SISI 1133.26
- MNPR N/A
- 52 Week Low
- SISI $4.71
- MNPR $3.65
- 52 Week High
- SISI $664.80
- MNPR $54.50
- Technical
- Relative Strength Index (RSI)
- SISI 59.66
- MNPR 74.00
- Support Level
- SISI $5.02
- MNPR $42.51
- Resistance Level
- SISI $6.80
- MNPR $45.78
- Average True Range (ATR)
- SISI 0.59
- MNPR 3.78
- MACD
- SISI 0.36
- MNPR 2.26
- Stochastic Oscillator
- SISI 90.61
- MNPR 91.64
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.